Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study

Naoki Ishiguro, Yoshiya Tanaka, Hisashi Yamanaka, Toshiyuki Yoneda, Takeshi Ohira, Naoki Okubo, Harry K. Genant, Désirée Van Der Heijde, Tsutomu Takeuchi

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Objectives. To evaluate the efficacy of denosumab for progressive bone erosion in risk factor subgroups of Japanese RA patients. Methods. This study included 340 RA patients on MTX from the dose-response study of Denosumab in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE study-a 12-month, multicentre, randomized, double-blind, placebo-controlled, phase II study). The patients were randomized to receive placebo or denosumab 60 mg every 6 months, 3 months or 2 months. Subgroup analyses involved baseline RF, ACPA, swollen joint count, CRP level, RA duration, ESR and glucocorticoid use. Results. Patients with risk factor positivity generally showed consistent results for the primary endpoint of the change in the modified Sharp erosion score at 12 months from baseline. In the placebo, every 6 months, every 3 months and every 2 months groups, the mean changes in the erosion score, according to the RF status (RF-positive vs -negative subgroups), were 1.18 vs 0.59, 0.25 (P = 0.0601 vs placebo) vs 0.31 (P = 0.0827), 0.21 (P = 0.0422) vs 0.02 (P = 0.0631) and 0.15 (P = 0.0010) vs 0.05 (P = 0.0332), respectively, while the mean changes in the erosion score, according to the ACPA status (ACPA-positive vs -negative subgroups), were 1.30 vs 0.07, 0.26 (P = 0.0142) vs 0.33 (P = 0.2748), 0.16 (P = 0.0058) vs 0.08 (P = 0.7166) and 0.09 (P < 0.0001) vs 0.08 (P = 0.8939), respectively. Conclusion. Denosumab is a potentially useful treatment option for RA patients who are positive for RF, ACPA and other possible risk factors. Trial registration.

Original languageEnglish
Pages (from-to)997-1005
Number of pages9
JournalRheumatology (United Kingdom)
Volume58
Issue number6
DOIs
Publication statusPublished - 2019

Keywords

  • Anti-cyclic citrullinated peptide antibody
  • Bone erosion
  • Denosumab
  • Rheumatoid arthritis
  • Rheumatoid factor
  • Subgroup analysis

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study'. Together they form a unique fingerprint.

Cite this